Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Dato-DXd Gets EU Panel Backing for Breast Cancer: Daiichi Sankyo
Daiichi Sankyo said on January 31 that its anti-TROP2 antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) has been recommended for regulatory approval in the EU for the treatment of certain breast cancer patients. The European Medicines Agency’s (EMA) Committee for…
To read the full story
Related Article
- FDA Approves Daiichi’s Datroway for EGFR Lung Cancer
June 25, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
- FDA Approves Daiichi’s New ADC Datroway for Breast Cancer
January 21, 2025
- Daiichi’s Revised Filing for TROP2 ADC Accepted for FDA Review
January 15, 2025
- Daiichi, AZ Pull EU Dato-DXd Filing for Lung Cancer
December 25, 2024
- Daiichi Sankyo’s TROP2 ADC Gets Breakthrough Therapy Tag in US
December 10, 2024
- Daiichi Sankyo Replaces FDA Lung Cancer Filing for TROP2-Directed ADC
November 13, 2024
- New Biomarker Analysis Data Out for Daiichi Sankyo’s TROP2 ADC
September 10, 2024
- Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- EU Regulators Accept Daiichi Sankyo’s TROP2 ADC for Review in Lung, Breast Cancers
March 5, 2024
- Daiichi Sankyo’s TROP2 ADC Now under US FDA Review for Lung Cancer
February 20, 2024
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…